MedTrace Logo

PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)

NCT00173524 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2009-05-19

No results posted yet for this study

Summary

The objective of this pharmacoeconomics (PE) study is to evaluate the cost- effectiveness analysis and cost-utility analysis of IRESSA® as first line treatment of NSCLC from the society perspective, based on resources and outcomes from patients who met the inclusion criteria for this naturalistic study comparing to existing first line platinum-based regimen chemotherapy.

Conditions

Interventions

BEHAVIORAL

PharmacoEconomic Assessment

Collecting PE data.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Lin Zone-Zhe, M.D. · Department of Oncology , National Taiwan University Hospital

  • Cheng Ann-Lii, M.D.,Ph.D. · Department of Oncology , National Taiwan University Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2005-09-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00173524 on ClinicalTrials.gov